MIRM
Mirum Pharmaceuticals, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
15.35
P/S
9.27
EV/EBITDA
347.82
DCF Value
$-3,572.28
FCF Yield
1.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
80.8%
Operating Margin
-4.2%
Net Margin
-4.5%
ROE
-8.5%
ROA
-2.8%
ROIC
-3.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $148.9M | $-5.7M | $-0.12 |
| FY 2025 | $521.3M | $-23.4M | $-0.47 |
| Q3 2025 | $133.0M | $2.9M | $0.05 |
| Q2 2025 | $127.8M | $-5.9M | $-0.12 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.52
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.